

David Collingridge, MD

Dr. David Collingridge has been Editor of *The Lancet Oncology* since March, 2002, after 6 months in the role of Senior Editor. Prior to his appointments at *The Lancet Oncology*, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK.

The Lancet Oncology

The Lancet Oncology was launched in September, 2000, as a lively monthly journal containing reviews, opinion, and news covering international issues relevant to clinical cancer specialists worldwide. In May, 2005, the journal expanded to include original research and began publishing articles Online First prior to print publication. The journal has quickly established itself as one of the premier publications worldwide for original research, especially reports from clinical trials. Uniquely, all original research is peer-reviewed via a fast-track service, and successful papers are published within 8 weeks of submission. In 2008, the journal expanded its online presence to include regular podcasts. *The Lancet Oncology* has an impact factor of 13.283. The journal is currently ranked sixth out of 141 cancer journals worldwide, and is in the top 1.5% of all scientific journals, of any discipline, globally (ISI Journal Citation Reports, 2008). Articles published in *The Lancet Oncology* regularly receive coverage in mainstream print, online, and broadcast media.

In 2007, *The Lancet Oncology* convened its first conference, held in Singapore, entitled Asia and Cancer Management in the 21st Century. Additionally in 2007, the journal hosted a plenary lecture at the Oncology Congress in San Francisco, CA, USA, on the topic of developmental biology, self renewal, and cancer. In subsequent years, the journal hosted a second plenary lecture at the 2008 Oncology Congress, and the inaugural Asian Oncology Summit in 2009. In 2010, *The Lancet Oncology's* involvement in conferences expanded with further events, including a second Asian Oncology Summit in Bali, Indonesia, and a conference on HPV and Cancer in Amsterdam, the Netherlands. Further events are planned for 2011 and beyond. The journal is also involved in cancer health-care advocacy by partnering with specific organisations.

